Featured Research

from universities, journals, and other organizations

New Clue To Diagnosis And Treatment Of Malignant Melanoma

Date:
January 15, 2001
Source:
Cold Spring Harbor Laboratory
Summary:
Malignant melanoma is an aggressive, deadly cancer that does not respond to conventional chemotherapy. Other aggressive, chemoresistant cancers — and approximately half of all cancers — are characterized by mutations in the p53 tumor suppressor gene. Malignant melanomas, however, do not typically display mutations in the p53 gene. To explore alternative explanations for the origins and properties of malignant melanoma, and to identify potential targets and strategies for therapy, Scott Lowe and his colleagues at Cold Spring Harbor Laboratory have examined the status of other genes known to function downstream of p53 in a pathway leading to "apoptosis" or "programmed cell death."

Cold Spring Harbor, NY -- Malignant melanoma is an aggressive, deadly cancer that does not respond to conventional chemotherapy. Other aggressive, chemoresistant cancers — and approximately half of all cancers — are characterized by mutations in the p53 tumor suppressor gene. Malignant melanomas, however, do not typically display mutations in the p53 gene.

Related Articles


To explore alternative explanations for the origins and properties of malignant melanoma, and to identify potential targets and strategies for therapy, Scott Lowe and his colleagues at Cold Spring Harbor Laboratory have examined the status of other genes known to function downstream of p53 in a pathway leading to "apoptosis" or "programmed cell death." When intact, this pathway rids the body of abnormal, pre-cancerous cells by triggering a cellular self-destruct mechanism. When this pathway is disrupted (by the loss of p53 function, for example), pre-cancerous cells survive and proliferate resulting in cancer (see figure).

In a study to be published tomorrow in Nature, Lowe and his colleagues report that malignant melanomas often lose a key trigger of programmed cell death — a protein called Apaf-1 (apoptosis activation factor-1). The researchers also discovered that the loss of Apaf-1 in melanoma cells is associated with resistance to the chemotherapy drug adriamycin. Most significantly, the study shows that restoring Apaf-1 in melanoma cells rescues the ability of these tumor cells to kill themselves in response to adriamycin.

"The loss of Apaf-1 in malignant melanoma is a prime explanation for both the extreme chemoresistance and the apparent lack of p53 defects in such cancers," says Lowe.

The study is significant because it demonstrates that accurate diagnosis and treatment of malignant melanoma, and perhaps other cancers, should include an assessment of the status of Apaf-1.

Maria Soengas of Cold Spring Harbor Laboratory was the principal author of the study. The principal collaborators in the study were William L. Gerald and Carlos Cordon-Cardo of Memorial Sloan-Kettering Cancer Center.

An intriguing aspect of the study relates to the mechanisms that cause the loss of Apaf-1 in melanomas. The researchers were not surprised to find that one of the two copies of the Apaf-1 gene was deleted in many of the melanomas they examined (a well-known phenomenon called "loss of heterozygosity"). However, the other Apaf-1 gene copy in these cells was present and apparently normal in terms of its DNA sequence. Interestingly, Lowe and his colleagues found that complete loss of Apaf-1 was due to "transcriptional silencing" of the remaining, normal copy of the Apaf-1 gene in melanomas. Transcriptional silencing, or the suppression of gene expression due to higher order chromatin structure, is emerging as a principle mechanism whereby Apaf-1 and other tumor suppressor genes can be inactivated, resulting in cancer when other copies of such genes are lost, mutated, or similarly silenced.

Scott Lowe is a Professor at Cold Spring Harbor Laboratory and Deputy Director of the Cold Spring Harbor Laboratory Cancer Center. Other scientists from Memorial Sloan-Kettering Cancer Center (Paolo Capodieci, David Polsky, Jaume Mora), Johns Hopkins University and Oncology Center (Manel Esteller, James G. Herman), and Cold Spring Harbor Laboratory (Ximena Opitz-Araya, W. Richard McCombie, Yuri A. Lazebnik) contributed to the study.


Story Source:

The above story is based on materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

Cold Spring Harbor Laboratory. "New Clue To Diagnosis And Treatment Of Malignant Melanoma." ScienceDaily. ScienceDaily, 15 January 2001. <www.sciencedaily.com/releases/2001/01/010111075020.htm>.
Cold Spring Harbor Laboratory. (2001, January 15). New Clue To Diagnosis And Treatment Of Malignant Melanoma. ScienceDaily. Retrieved April 21, 2015 from www.sciencedaily.com/releases/2001/01/010111075020.htm
Cold Spring Harbor Laboratory. "New Clue To Diagnosis And Treatment Of Malignant Melanoma." ScienceDaily. www.sciencedaily.com/releases/2001/01/010111075020.htm (accessed April 21, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, April 21, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Teva Offers $40 Billion for Mylan

Teva Offers $40 Billion for Mylan

Reuters - Business Video Online (Apr. 21, 2015) Generic drugmaker Teva Pharmaceutical is offering $82 a share, or $40 billion, for its smaller rival Mylan, in an alternative to Mylan&apos;s deal to buy Perrigo. Bobbi Rebell reports. Video provided by Reuters
Powered by NewsLook.com
Blue Bell Recalls All Products

Blue Bell Recalls All Products

AP (Apr. 21, 2015) Blue Bell Creameries voluntary recalled for all of its products after two samples of chocolate chip cookie dough ice cream tested positive for listeria, a potentially deadly bacteria. Blue Bell&apos;s President and CEO issued a video statement. (April 21) Video provided by AP
Powered by NewsLook.com
Yemen Doctors at Breaking Point

Yemen Doctors at Breaking Point

Reuters - News Video Online (Apr. 21, 2015) A Sanaa hospital struggles to cope with the high number of casualties with severe injuries, after an air strike left at least 25 dead and hundreds wounded. Deborah Lutterbeck reports. Video provided by Reuters
Powered by NewsLook.com
'Tutu Tuesdays' Brighten Faces at Kids' Hospital

'Tutu Tuesdays' Brighten Faces at Kids' Hospital

AP (Apr. 21, 2015) Doctors and nurses have started wearing ballet tutus every Tuesday to cheer up young hospital patients at a Florida hospital. It started with a request made by a nervous patient -- now, almost the entire staff is wearing the tutus. (April 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins